AstraZeneca said on Friday it will spend Ksh.323 billion on a research and development hub in Beijing, as the drugmaker ...

In a bold move to cement its foothold in China’s booming biopharmaceutical sector, AstraZeneca announced Friday a $2.5 billion investment in Beijing over the next five years. The pharmaceutical titan ...

AstraZeneca has announced a $2.5 billion investment in a research and development hub in Beijing, underscoring its commitment ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

The $2.5 billion investment reflects AstraZeneca's continued commitment to China, Chief Executive Pascal Soriot said. The R&D facility will be the company's second in China, coming after its research ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Syneron Bio has partnered with AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of ...

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...